Transplant diagnostics firm CareDx Q3 revenue beats estimates, helped by new product launches

Reuters11-05
Transplant diagnostics firm <a href="https://laohu8.com/S/CDNA">CareDx</a> Q3 revenue beats estimates, helped by new product launches

Overview

  • CareDx Q3 revenue rose 21% yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

  • Company raised 2025 revenue guidance to $372 mln-$376 mln

Outlook

  • CareDx raises 2025 revenue guidance to $372 mln to $376 mln

  • Company increases 2025 adjusted EBITDA guidance to $35 mln to $39 mln

Result Drivers

  • TESTING SERVICES - Testing services revenue increased 19% yr/yr, driven by a 13% rise in testing volume

  • NEW PRODUCT LAUNCHES - Introduction of AlloSeq Tx11 and HistoMap Kidney supported revenue growth

  • INNOVATION IN TRANSPLANT SOLUTIONS - New products like HistoMap Kidney and AlloSure Heart contributed to growth

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$100 mln

$95.25 mln (8 Analysts)

Q3 Adjusted EPS

Beat

$0.28

$0.14 (6 Analysts)

Q3 EPS

$0.03

Q3 Adjusted Net Income

Beat

$14.90 mln

$7.48 mln (6 Analysts)

Q3 Net Income

$1.70 mln

Q3 Adjusted EBITDA

Beat

$15.30 mln

$7.93 mln (6 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for CareDx Inc is $23.00, about 35.8% above its November 3 closing price of $14.77

  • The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release: ID:nBw84W8T5a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment